Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,119,070
  • Shares Outstanding, K 73,478
  • Annual Sales, $ 40,890 K
  • Annual Income, $ -199,590 K
  • 60-Month Beta 1.44
  • Price/Sales 27.40
  • Price/Cash Flow N/A
  • Price/Book 8.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.73
  • Number of Estimates 7
  • High Estimate -0.60
  • Low Estimate -0.82
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -8.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.09 +0.93%
on 08/07/20
20.00 -23.85%
on 07/10/20
-3.86 (-20.22%)
since 07/07/20
3-Month
15.09 +0.93%
on 08/07/20
21.82 -30.20%
on 05/26/20
-4.23 (-21.74%)
since 05/07/20
52-Week
8.02 +89.90%
on 09/04/19
29.61 -48.56%
on 03/02/20
+6.53 (+75.06%)
since 08/07/19

Most Recent Stories

More News
Downtrend Call Working As Karyopharm Thera Stock Falls 20.8% (KPTI)

SmarTrend identified a Downtrend for Karyopharm Thera (NASDAQ:KPTI) on May 6th, 2020 at $19.44. In approximately 3 months, Karyopharm Thera has returned 20.83% as of today's recent price of $15.39.

KPTI : 15.23 (-0.13%)
Watch for Karyopharm Thera to Potentially Rebound After Falling 3.44% Yesterday

Karyopharm Thera (NASDAQ:KPTI) traded in a range yesterday that spanned from a low of $15.45 to a high of $16.50. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...

KPTI : 15.23 (-0.13%)
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?...

KPTI : 15.23 (-0.13%)
Karyopharm Therapeutics: 2Q Earnings Snapshot

NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Tuesday reported a loss of $46.4 million in its second quarter.

KPTI : 15.23 (-0.13%)
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended . In...

KPTI : 15.23 (-0.13%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock...

KPTI : 15.23 (-0.13%)
Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on . Karyopharm's management...

KPTI : 15.23 (-0.13%)
U.S. Food and Drug Administration Accepts Karyopharm's Supplemental New Drug Application for XPOVIO(R) (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug...

KPTI : 15.23 (-0.13%)
Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO(R) (selinexor) Research

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National...

KPTI : 15.23 (-0.13%)
Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO(R) (selinexor)

-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the Second Quarter 2020 --

KPTI : 15.23 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade KPTI with:

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

2nd Resistance Point 16.02
1st Resistance Point 15.62
Last Price 15.23
1st Support Level 14.96
2nd Support Level 14.70

See More

52-Week High 29.61
Fibonacci 61.8% 21.36
Fibonacci 50% 18.82
Fibonacci 38.2% 16.27
Last Price 15.23
52-Week Low 8.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar